Brief: BioArctic's Leqembi Approved For Treatment Of Early Alzheimer's Disease In Australia
24/09/2025 07:42
Sept 24 (Reuters) - BioArctic AB BIOAb.ST: LEQEMBI APPROVED FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE IN AUSTRALIA Source text: ID:nWkrbt5HPK Further company coverage: [BIOAb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln